NCT05971758View on ClinicalTrials.gov

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions

Cushing Disease

Interventions

DRUG

Fimepinostat

The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.

Trial Locations (1)

90095

RECRUITING

Ronald Reagan Medical Center, Los Angeles

All Listed Sponsors

lead

University of California, Los Angeles

OTHER